Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of CLDN18.2-targeting Chimeric Antigen Receptor-modified Autologous T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

NCT05472857 is registered in ClinicalTrials.gov with Suzhou Immunofoco Biotechnology Co., Ltd as lead sponsor.

NCT NCT05472857
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05472857 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of CLDN18.2-targeting Chimeric Antigen Receptor-modified Autologous T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression
Lead sponsor
Suzhou Immunofoco Biotechnology Co., Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
August 8, 2022
Completion date
December 31, 2024
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced ovarian carcinoma, gastric cancer, gastroesophageal junction adenocarcinoma, pancreatic cancer